<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-title>BMC Neurology</journal-title><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15476562</article-id><article-id pub-id-type="pmc">PMC524508</article-id><article-id pub-id-type="publisher-id">1471-2377-4-15</article-id><article-id pub-id-type="doi">10.1186/1471-2377-4-15</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Lack of association between vascular dementia and Chlamydia pneumoniae infection: a case-control study</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Chan Carusone</surname><given-names>Soo</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>chansy@mcmaster.ca</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Smieja</surname><given-names>Marek</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>smiejam@mcmaster.ca</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Molloy</surname><given-names>William</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>wmolloy@stpetes.ca</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Goldsmith</surname><given-names>Charlie H</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>goldsmit@mcmaster.ca</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Mahony</surname><given-names>Jim</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>mahonyj@mcmaster.ca</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Chernesky</surname><given-names>Max</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>chernesk@mcmaster.ca</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Gnarpe</surname><given-names>Judy</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>judy.gnarpe@ualberta.ca</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Standish</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>tstandish@stpetes.ca</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Smith</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>smithste@mcmaster.ca</email></contrib><contrib id="A10" corresp="yes" contrib-type="author"><name><surname>Loeb</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>loebm@mcmaster.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Clinical Epidemiology and Biostatistics, McMaster University, 1200 Main St. W., L8N 3Z5 Hamilton, Canada</aff><aff id="I2"><label>2</label>Department of Pathology and Molecular Medicine, McMaster University, 1200 Main St. W., L8N 3Z5 Hamilton, Canada</aff><aff id="I3"><label>3</label>Hamilton Regional Laboratory Medicine Program, 50 Charlton Ave. E., L8N 4A6 Hamilton, Canada</aff><aff id="I4"><label>4</label>St. Peter's Centre for Studies in Aging, St. Peter's Hospital, 88 Maplewood Ave., L8M 1W9 Hamilton, Canada</aff><aff id="I5"><label>5</label>Department of Medicine, McMaster University, 1200 Main St. W., L8N 3Z5 Hamilton, Canada</aff><aff id="I6"><label>6</label>Department of Medical Microbiology and Immunology, University of Alberta, T6G 2H7 Edmonton, Canada</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>12</day><month>10</month><year>2004</year></pub-date><volume>4</volume><fpage>15</fpage><lpage>15</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2377/4/15"/><history><date date-type="received"><day>3</day><month>6</month><year>2004</year></date><date date-type="accepted"><day>12</day><month>10</month><year>2004</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2004 Carusone et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Carusone et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Chan Carusone
               Soo
               
               chansy@mcmaster.ca
            </dc:author><dc:title>
            Lack of association between vascular dementia and Chlamydia pneumoniae infection: a case-control study
         </dc:title><dc:date>2004</dc:date><dcterms:bibliographicCitation>BMC Neurology 4(1): 15-. (2004)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2377(2004)4:1&#x0003c;15&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2377</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Chronic inflammation appears to play a role in the pathogenesis of vascular dementia. Given the association between <italic>Chlamydia pneumoniae </italic>and stroke, the possibility exists that previous exposure to <italic>C. pneumoniae </italic>may play a role in vascular dementia. The objective of this study was to determine if there was an association between serological evidence of <italic>C. pneumoniae </italic>infection or inflammatory markers with vascular dementia.</p></sec><sec sec-type="methods"><title>Methods</title><p>28 case-patients with vascular dementia at a geriatric clinic and 24 caregiver-controls were tested for <italic>C. pneumoniae </italic>IgG and IgA antibodies. The association between vascular dementia and <italic>C. pneumoniae </italic>titres as well as inflammatory markers was estimated by using both conditional logistic regression and stratified logistic regression.</p></sec><sec><title>Results</title><p>When matched cases were compared to controls, there was no significant difference in elevated <italic>C. pneumoniae </italic>specific IgG antibodies (titre &#x02265; 1:32), odds ratio [OR] 1.3 (95% confidence intervals [CI] 0.3 to 6.0), p = 0.71, or in elevated <italic>C. pneumoniae </italic>specific IgA antibodies (titre &#x02265; 1:16), OR 2.0 (95%CI 0.5 to 8.0), p = 0.33 indicative of past or persistent <italic>C. pneumoniae </italic>infection. Similarly, no difference in high IgG or IgA antibody levels (IgG titre &#x02265; 1:512 or IgA titre &#x02265; 1:64) between the two groups, indicative of recent <italic>C. pneumoniae </italic>infection, was found, OR 0.4 (95%CI 0.1 to 2.1), p = 0.27. For C-reactive protein (CRP), the mean difference between 18 matched pairs (case &#x02013; control) was &#x02013; 3.33 mg/L. There was no significant difference between cases and controls when comparing log transformed values, OR 0.03 (95%CI 0.00 to 2.89), p = 0.13 or comparing CRP values above or below the median, OR 0.8 (95%CI 0.2 to 3.4), p = 0.71. For fibrinogen, the mean difference between pairs (case &#x02013; control) was -0.07 g/L. There was no statistical difference between cases and controls when comparing log transformed values, OR 0.6 (95%CI 0.0 to 31.2), p = 0.79 or between fibrinogen values above and below the median, OR = 0.5 (95%CI 0.1 to 2.0), p = 0.50.</p></sec><sec><title>Conclusion</title><p>We found no evidence for a significant association between <italic>C. pneumoniae </italic>infection, inflammatory markers such as CRP and fibrinogen, and vascular dementia.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Vascular dementia is characterized by a loss of cognitive function and social adaptive functions in individuals with cerebrovascular disease [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Vascular dementia is the second most common cause of dementia and accounts for 10% to 15% of all cases [<xref ref-type="bibr" rid="B3">3</xref>]. The clinical presentation of this illness is variable, depending on the site and extent of the lesion or infarct [<xref ref-type="bibr" rid="B2">2</xref>]. The pathogenesis of vascular dementia has not been well defined [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Chronic inflammation and cytokine dysregulation may play a role [<xref ref-type="bibr" rid="B4">4</xref>] similar to that seen in Alzheimer's disease [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Recent data from serological and PCR studies support an association between <italic>Chlamydia pneumoniae </italic>and cerebrovascular disease. <italic>C. pneumoniae </italic>has been associated with stroke, transient cerebral ischemia, and atherosclerosis in the middle cerebral artery in both prospective and case-control studies [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. Since stroke is an important precursor to vascular dementia, these data raise the possibility that <italic>C. pneumoniae </italic>infection may also be a risk factor for vascular dementia. To our knowledge, this potential relationship has not previously been assessed. We conducted a pilot case-control study to determine an association between serological evidence of <italic>C. pneumoniae </italic>infection and vascular dementia. We also sought to determine if the inflammatory markers, C-reactive protein (CRP) and fibrinogen were associated with this illness.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study design</title><p>Patients with vascular dementia were enrolled from the Geriatric Clinic at Henderson Hospital, an outpatient clinic affiliated with a tertiary hospital in Hamilton, Ontario. The diagnosis of vascular dementia for participants enrolled was determined in accordance with criteria established by the Neuroepidemiology Branch of the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) International workshop [<xref ref-type="bibr" rid="B13">13</xref>]. This includes both physical and imaging evidence of strokes, and a temporal relationship between stroke and dementia [<xref ref-type="bibr" rid="B3">3</xref>]. Case-patients meeting any of the following criteria were excluded: 1) cognitive impairment due to acute cerebral trauma, hypoxic cerebral damage post cardiac arrest, vitamin deficiency states, central nervous system infection, cerebral neoplasia, significant endocrine or metabolic disease, mental retardation; 2) stroke within the last 6 weeks; 3) patients known, in the past 3 months, to have taken a 7 day or more course of antibiotics with activity against <italic>C. pneumoniae </italic>(erythromycin, clarithromycin, azithromycin, levofloxacin, trovafloxacin, doxycycline, or tetracycline).</p><p>The controls for this study were chosen from a list of all caregivers who attended the geriatric clinic at the time of the study, regardless of the diagnosis of their spouse or family member. For each case, one caregiver matched for age (within five years) and sex was selected. Caregivers were excluded if they had a diagnosis that included any of the following: dementia, stroke, or cognitive impairment as determined by a Standardized Mini-Mental Status Examination score of &#x0003c; 27 [<xref ref-type="bibr" rid="B14">14</xref>]. Enrolment was from July 1999 to October 2001. All eligible cases and controls who attended the clinic during the study period were approached for consent to participate in the study. Demographic data (age, sex), medical history, and smoking history were collected as well as blood samples for <italic>C. pneumoniae </italic>IgG and IgA antibodies, CRP, and fibrinogen.</p><p>This study was approved by the research ethics board at McMaster University. Signed consent was obtained for all participants (proxy consent was utilized for participants considered decisionally impaired).</p></sec><sec><title>Laboratory methods</title><p>For <italic>C. pneumoniae </italic>IgG and IgA antibody detection, all sera were titrated at two-fold dilutions from 1:16 to endpoint. Samples were analyzed by microimmunofluorescence (MIF), using a 16 hour incubation of serum and substrate at 4&#x02013;8&#x000b0;C with the same batch of <italic>C. pneumoniae </italic>IgG/IgM MIF slides (LabSystems OY, Helsinki) (23). To prevent IgG interference, sera used for IgA detection were first treated with goat anti-human IgG antibodies (GullSorb; Gull Laboratories, Salt Lake City, UT, USA). CRP was measured using a high sensitivity automated rate nephelometric immunoassay (Dade Behring high-sensitivity CRP, BNII Nephelometer System, Marburc, DE). Fibrinogen was assayed using an automated STA fibrinogen assay (von Clauss method) on a Roche/Stago (Diagnostica Stago SA).</p></sec><sec><title>Analysis</title><p>The presence of elevated antibody levels, indicative of past or persistent <italic>C. pneumoniae </italic>infection, was defined as an IgG titre of 1:32 or greater and IgA of 1:16 or greater [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. High antibody titres to <italic>C. pneumoniae</italic>, suggesting a more recent infection, was defined by IgG titres of 1:512 or greater or IgA titres of 1:64 or greater [<xref ref-type="bibr" rid="B16">16</xref>]. Because a skewed distribution was anticipated and a linear relationship with risk was not expected, CRP and fibrinogen were analyzed in two ways: using a log transformation of the values and dichotomizing at the median.</p><p>The association between vascular dementia and <italic>C. pneumoniae </italic>titres and inflammatory markers was estimated using a matched analysis. Conditional logistic regression analyses were performed for antibody levels, dichotomized and log transformed CRP, as well as dichotomized and log transformed fibrinogen.</p><p>A stratified logistic regression analysis was also conducted for <italic>C. pneumoniae </italic>titres and inflammatory markers (both log transformed and dichotomized at the median), stratifying by age and sex (the following age strata were used: &#x02264; 70 years, 71&#x02013;80 years, 81&#x02013;90 years). All analyses for <italic>C. pneumoniae </italic>titres and inflammatory markers were also performed with adjustment for current smoking status. Data analyses were performed with SPSS version 10 or Egret for Windows version 2.0.3.</p><p>The original protocol involved two concurrent case-control studies: one including 30 vascular dementia patients and 30 controls and the other with 30 Alzheimer disease patients and 30 controls. The analysis was to include the additional 30 Alzheimer disease controls in the vascular dementia analysis (giving a 1:2 case:control ratio). Assuming that one third of controls would have elevated <italic>C. pneumoniae </italic>titres, for an alpha of 0.05 and 80% power, matching 30 cases to 60 controls would allow for detection of an odds ratio of 3.8 or higher. As the study proceeded, it became apparent that enrolling the Alzheimer's patients was not feasible. We decided then to limit the analysis to a 1:1 case:control ratio focusing on 30 patients with vascular dementia.</p></sec></sec><sec><title>Results</title><sec><title>Participants</title><p>A total of 28 case-patients were enrolled: mean age 76.2 years (minimum to maximum: 56 to 90 years); 18 (64%) were male. Nine of the 28 cases had at least one comorbidity (including angina, coronary heart disease, vascular disease, liver disease and renal disease); 1 case had 3 or more comorbidities. Thirteen of the cases were current smokers.</p><p>Twenty of the 28 cases could be matched to caregiver-controls, for a total of 20 case-control pairs. Of these 20 caregiver-controls, 16 were unrelated to a case, and four were spouses of a case. However, none of these four were matched to their spouse. Four additional caregiver-controls were selected for the unmatched analyses, so that data on a total of 24 caregiver-controls was obtained.</p><p>Where there was incomplete data on antibody or inflammatory marker levels, those pairs were excluded from matched analyses. Incomplete information on cases and controls occurred when individuals consented to participate in the study and provided medical information but did not attend the out-patient clinic for the required blood collection. All individuals with complete data were included in the unmatched analyses.</p></sec><sec><title><italic>C. pneumoniae </italic>serology</title><p>Univariate analysis of <italic>C. pneumoniae </italic>specific IgG antibodies showed no statistically significant difference in elevated antibody levels between matched case-patients and controls, odds ratio [OR] = 1.3 (95% confidence intervals [CI] 0.3 to 6.0), p = 0.71. When pairs were broken and stratified analyses were performed the difference was not statistically significant, OR = 1.8 (95%CI 0.4 to 8.3), p = 0.46. The analysis was also performed with adjustment for participants' current smoking status, OR = 1.8 (95%CI 0.2 to 12.2), p = 0.57 (see Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Comparison of analyses used to assess for associations of <italic>C. pneumoniae </italic>specific serology and vascular dementia</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Variable</bold></td><td align="center" colspan="3"><bold>Conditional</bold></td><td align="center" colspan="3"><bold>Stratified*</bold></td><td align="center" colspan="3"><bold>Adjusted**</bold></td></tr><tr><td></td><td colspan="9"><hr></hr></td></tr><tr><td></td><td align="center"><bold>OR</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>n<sup>1</sup></bold></td><td align="center"><bold>OR</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>n<sup>2</sup></bold></td><td align="center"><bold>OR</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>n<sup>2</sup></bold></td></tr></thead><tbody><tr><td align="left">IgG response</td><td align="left">1.5</td><td align="left">0.66</td><td align="left">15</td><td align="left">1.8</td><td align="left">0.46</td><td align="left">48</td><td align="left">1.7</td><td align="left">0.50</td><td align="left">48</td></tr><tr><td align="left">IgA response</td><td align="left">1.7</td><td align="left">0.48</td><td align="left">15</td><td align="left">2.8</td><td align="left">0.13</td><td align="left">48</td><td align="left">3.0</td><td align="left">0.11</td><td align="left">48</td></tr><tr><td align="left">High titre response</td><td align="left">0.4</td><td align="left">0.27</td><td align="left">15</td><td align="left">0.6</td><td align="left">0.40</td><td align="left">48</td><td align="left">0.5</td><td align="left">0.34</td><td align="left">48</td></tr></tbody></table><table-wrap-foot><p><sup>1 </sup>Number of pairs included in the analysis</p><p><sup>2 </sup>Number of individuals included in the analysis</p><p>* Stratified on age (&#x02264; 70 years, 71&#x02013;80 years, 81&#x02013;90 years) and gender</p><p>**Stratified analysis with adjustment for current smoking status</p></table-wrap-foot></table-wrap><p>Similarly, no statistically significant difference between elevated <italic>C. pneumoniae </italic>specific IgA antibodies was found between matched pairs, OR = 2.0 (95%CI 0.5 to 8.0), p = 0.33. The stratified analysis produced slightly higher odds ratio estimates, although not statistically significant. For the unadjusted analysis, OR = 2.8 (95%CI 0.7 to 10.4), p = 0.13 and for the adjusted analysis, OR = 2.7 (95%CI 0.5 to 14.2), p = 0.24 (see Table <xref ref-type="table" rid="T1">1</xref>).</p><p>There was also no statistical difference in high antibody levels between matched pairs, OR = 0.4 (95%CI 0.1 to 2.1), p = 0.27 or in the stratified analysis, OR = 0.6 (95%CI 0.2 to 2.0), p = 0.40 for the unadjusted analysis and OR = 0.5 (95%CI 0.1 to 2.5), p = 0.41 for the adjusted analysis (see Table <xref ref-type="table" rid="T1">1</xref>).</p></sec><sec><title>Inflammatory markers</title><p>A matched analysis of CRP performed on 18 of the 20 matched pairs (all pairs with complete data) revealed no significant difference between log-transformed values, OR of 0.03 (95%CI 0.00 to 2.89), p = 0.13. Similarly, there was no difference comparing matched cases and controls with CRP values above or below the median, OR = 0.8 (95%CI 0.2 to 3.4), p = 0.71. In the stratified analysis (Table <xref ref-type="table" rid="T2">2</xref>), the log transformed CRP variable and the CRP variable dichotomized at the median were not statistically significant in both the unadjusted (OR = 0.5 (95%CI 0.1 to 3.6), p = 0.50 and OR = 2.2 (95%CI 0.7 to 7.2), p = 0.20, respectively) and the adjusted analysis (OR = 0.4 (95%CI 0.04 to 4.7), p = 0.49 and OR = 1.4 (95%CI 0.3 to 6.3), p = 0.64, respectively).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Comparison of analyses used to assess for associations of inflammatory markers and vascular dementia</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Variable</bold></td><td align="center" colspan="3"><bold>Conditional</bold></td><td align="center" colspan="3"><bold>Stratified*</bold></td><td align="center" colspan="3"><bold>Adjusted**</bold></td></tr><tr><td></td><td colspan="9"><hr></hr></td></tr><tr><td></td><td align="center"><bold>OR</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>n<sup>1</sup></bold></td><td align="center"><bold>OR</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>n<sup>2</sup></bold></td><td align="center"><bold>OR</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>n<sup>2</sup></bold></td></tr></thead><tbody><tr><td align="left">LogCRP</td><td align="left">0.0</td><td align="left">0.13</td><td align="left">18</td><td align="left">0.5</td><td align="left">0.50</td><td align="left">49</td><td align="left">0.5</td><td align="left">0.52</td><td align="left">49</td></tr><tr><td align="left">CRP</td><td align="left">0.8</td><td align="left">0.71</td><td align="left">18</td><td align="left">2.2</td><td align="left">0.20</td><td align="left">49</td><td align="left">2.2</td><td align="left">0.19</td><td align="left">49</td></tr><tr><td align="left">LogFibrinogen</td><td align="left">0.6</td><td align="left">0.79</td><td align="left">18</td><td align="left">0.8</td><td align="left">0.92</td><td align="left">49</td><td align="left">0.6</td><td align="left">0.83</td><td align="left">49</td></tr><tr><td align="left">Fibrinogen</td><td align="left">0.5</td><td align="left">0.33</td><td align="left">18</td><td align="left">0.6</td><td align="left">0.38</td><td align="left">49</td><td align="left">0.5</td><td align="left">0.32</td><td align="left">49</td></tr></tbody></table><table-wrap-foot><p><sup>1 </sup>Number of pairs included in the analysis</p><p><sup>2 </sup>Number of individuals included in the analysis</p><p>* Stratified on age (&#x02264; 70 years, 71&#x02013;80 years, 81&#x02013;90 years) and gender</p><p>**Stratified analysis with adjustment for current smoking status</p></table-wrap-foot></table-wrap><p>A matched analysis of fibrinogen performed on the same 18 pairs revealed no significant difference between the log-transformed values of the two groups, OR = 0.6 (95%CI 0.0 to 31.2), p = 0.79. Similarly, there was no difference when comparing the pairs on fibrinogen values above and below the median, OR = 0.5 (95%CI 0.1 to 2.0), p = 0.33. In the stratified analysis (Table <xref ref-type="table" rid="T2">2</xref>), the log transformed fibrinogen variable and the fibrinogen variable dichotomized at the median were not statistically significant in both the unadjusted (OR = 0.8 (95%CI 0.0 to 71.6), p = 0.92 and OR = 0.6 (95%CI 0.2 to 2.0), p = 0.38, respectively) and the adjusted analysis (OR = 0.1 (95%CI 0.0 to 73.9), p = 0.43 and OR = 0.3 (95%CI 0.1 to 1.6), p = 0.17, respectively).</p></sec></sec><sec><title>Discussion</title><p>In this case-control study, we found no significant association between elevated or high <italic>C. pneumoniae </italic>specific IgG or IgA antibodies and vascular dementia. To our knowledge, this is the first epidemiologic study to test for an association between vascular dementia and infection with <italic>C. pneumoniae</italic>.</p><p>We conducted this study on the basis of evidence linking <italic>C. pneumoniae </italic>to cardiovascular disease and stroke. There is an extensive literature supporting an association between <italic>C. pneumoniae </italic>and atherosclerosis [<xref ref-type="bibr" rid="B17">17</xref>-<xref ref-type="bibr" rid="B19">19</xref>]. Although the majority of these studies initially focused on coronary heart disease more recent evidence also supports an association with stroke [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. However, the clinical importance of this association is uncertain.</p><p>Although no significant associations were noted, the relatively small sample size and the odds ratio estimates for elevated IgA and IgG antibodies do not definitively rule out an association. In fact, we powered this study to detect a minimally important association between antibodies and vascular dementia of 3.8. Given that the odds ratio 95% confidence interval of IgG is from 0.3 to 6.0, and 0.5 to 8.0 for IgA, our data do not rule out clinically important associations. The point estimates for elevated IgA and IgG antibodies (2.0 and 1.3, respectively) are similar to the recent meta-analysis odds ratio estimates for coronary heart disease of 1.25 (95% CI 1.03 to 1.53) and 1.15 (95% CI 0.97 to 1.36), respectively [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. In both cases the odds ratio estimate for IgA titres is slightly higher than IgG titres, but not statistically different. The meaning of this difference is uncertain. Danesh et al [<xref ref-type="bibr" rid="B21">21</xref>] suggest that these differences are likely due to chance, selection biases, or selective emphasis on particular reports. In contrast, other studies have suggested that IgA titres are more strongly associated with disease outcomes because they are a better indicator of chronic <italic>C. pneumoniae </italic>infection [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Vascular dementia is the second most common cause of dementia, second only to Alzheimer's disease. It was previously believed that most cases of dementia were the outcome of one of these two distinct diseases. However, the clear division between them has recently been challenged. It is now widely believed that vascular risk factors are also associated with Alzheimer's disease and Alzheimer's and vascular dementia may share many common clinical and pathological characteristics [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. A number of studies have examined the association between Alzheimer's disease and <italic>C. pneumoniae </italic>infection. In 1998 Balin et al [<xref ref-type="bibr" rid="B27">27</xref>] found an extremely high association between the presence of <italic>C. pneumoniae </italic>in post-mortem brain samples and late-onset Alzheimer's disease. However, more recent studies have not repeated these findings [<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. A recent randomized controlled clinical trial [<xref ref-type="bibr" rid="B16">16</xref>], based on the hypothesis that chronic <italic>C. pneumoniae </italic>infection contributes to Alzheimer's disease, found an improved long-term cognitive state in patients with mild to moderate Alzheimer's disease who had been treated with doxycycline and rifampin. However, the serological data did not suggest that this clinical effect was due to treatment of chronic <italic>C. pneumoniae </italic>infection. One study has looked for <italic>C. pneumoniae </italic>in brain samples of vascular dementia patients. This study, like the later AD studies, did not identify <italic>C. pneumoniae </italic>in any of the brain samples [<xref ref-type="bibr" rid="B32">32</xref>]. These results suggest that the presence of <italic>C. pneumoniae </italic>in the brains is not strongly associated with late-onset Alzheimer's disease or vascular dementia.</p><p>Inflammatory responses are also known to be associated with cardiovascular disease and have recently been implicated in dementia [<xref ref-type="bibr" rid="B33">33</xref>]. Elevated levels of serum C-reactive protein (CRP), a non-specific marker of inflammation, predict cardiovascular disease [<xref ref-type="bibr" rid="B34">34</xref>] and dementia [<xref ref-type="bibr" rid="B33">33</xref>], and have been associated with stroke patients [<xref ref-type="bibr" rid="B35">35</xref>]. Recently, an association between inflammatory markers alpha 1-antichymotrypsin, interleukin 6, and, to a lesser extent, C-reactive protein were associated with an increased risk of dementia [<xref ref-type="bibr" rid="B36">36</xref>]. In this study we did not find a significant difference in CRP levels between the cases and controls. This most likely was due to the limited power in the study and the limitations of measuring serum CRP. Although CRP was originally thought to be produced almost exclusively by hepatocytes, CRP is now known to be synthesized in brain cells and upregulated in Alzheimer tissue [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. Consequently, localized increases in CRP may be associated with vascular dementia but not detected with serum measurements.</p><p>We found no significant association between increased fibrinogen levels and vascular dementia. Abnormalities of haemostasis are thought to be important in the pathogenesis of cardiovascular disease, ischaemic stroke, and vascular dementia. Within the pathways of coagulation and fibrinolysis, fibrinogen represents an important marker. Elevated levels of fibrinogen are associated with increased risks of cardiovascular disease and ischaemic stroke [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>] but the results are less conclusive for vascular dementia [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>]. Lowe and Haverkate [<xref ref-type="bibr" rid="B43">43</xref>] believe that because vascular dementia is only one phenotype of the systemic atherothrombosis disease, associations between haemostatic variables and any given phenotype should be interpreted with caution. To show a specific association with a single phenotype, a study would need an extremely large sample size to overcome the overlap in phenotypes and risk factors seen in atherothrombosis.</p><p>We acknowledge several limitations of this study. Because of the relatively small sample size, the analyses were adjusted for only a small number of potentially important covariates and the analysis of CRP and fibrinogen was restricted to above and below the median (while quartiles would have been more sensitive). To adjust for variables that were not used as matching criteria and to maximize the data collected a stratified analysis was also done. The additional stratified analysis adjusted for current smoking status. We adjusted for smoking status because there is a known strong association between smoking and <italic>C. pneumoniae </italic>titres; and between smoking and vascular dementia [<xref ref-type="bibr" rid="B44">44</xref>]. However, it may also be important to adjust for additional factors that may affect inflammatory markers. We also acknowledge that <italic>C. pneumoniae </italic>serology is an imperfect test of <italic>C. pneumoniae </italic>exposure and chronic infection. First, the high prevalence of <italic>C. pneumoniae </italic>exposure makes it difficult to detect true serological differences between cases and controls. Second, it is unclear what the appropriate serological cut-offs should be for identifying exposure versus chronic infection or recent infections. As a result, different groups have used different criteria making comparisons across studies more difficult. However, the importance of this inconsistency is unclear. In the meta-analysis reported by Danesh et al [<xref ref-type="bibr" rid="B21">21</xref>] no significant heterogeneity was found among the studies even though four different cut-off titres were used to determine seropositivity in the microimmunofluorescence assays. An alternative test, that may prove to be more reliable, involves the detection of <italic>C. pneumoniae </italic>DNA in peripheral blood mononuclear cells [<xref ref-type="bibr" rid="B45">45</xref>]. Another potential limitation is the choice of controls; because <italic>C. pneumoniae </italic>is infectious an increased exposure in the caregivers could potentially mask a statistically significant association between the patients and controls. There is also evidence that caregivers, because of stress, may have altered immune systems [<xref ref-type="bibr" rid="B46">46</xref>] which could interfere with their generation of antibodies and inflammatory markers [<xref ref-type="bibr" rid="B47">47</xref>-<xref ref-type="bibr" rid="B49">49</xref>].</p></sec><sec><title>Conclusions</title><p>In summary, a case-control study of vascular dementia patients suggests that there is no significant association between <italic>C. pneumoniae </italic>antibodies and vascular dementia. We found no evidence for a significant association between systemic inflammatory markers and vascular dementia. While this study can rule out a strong association, larger studies are necessary to determine if a weak association exists.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>ML, MS, WM, CG, JM, and MC conceived and designed the original study. SCC conducted the analysis of data and drafted the manuscript. SS and TS coordinated the study and collected data. JG conducted the serological testing. All authors offered critical input into the manuscript and all have read and approved the final version.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2377/4/15/prepub"/></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strub</surname><given-names>R</given-names></name></person-group><article-title>Vascular dementia</article-title><source>South Med J</source><year>2003</year><volume>96</volume><fpage>363</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">12916555</pub-id><pub-id pub-id-type="doi">10.1097/01.SMJ.0000063470.95541.6B</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Leeuw</surname><given-names>FE</given-names></name><name><surname>van Gijn</surname><given-names>J</given-names></name></person-group><article-title>Vascular dementia</article-title><source>Practical Neurology</source><year>2003</year><volume>3</volume><fpage>86</fpage><lpage>91</lpage></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>J</given-names></name></person-group><article-title>Vascular dementia</article-title><source>J Am Med Dir Assoc</source><year>2003</year><volume>4</volume><fpage>S155</fpage><lpage>S161</lpage><pub-id pub-id-type="pmid">14613592</pub-id><pub-id pub-id-type="doi">10.1097/01.JAM.0000095365.40379.04</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>CJ</given-names></name><name><surname>Finch</surname><given-names>CE</given-names></name><name><surname>Cohen</surname><given-names>HJ</given-names></name></person-group><article-title>Cytokines and cognition &#x02013; the case for a head-to-toe inflammatory paradigm</article-title><source>J Am Geriatr Soc</source><year>2002</year><volume>50</volume><fpage>2041</fpage><lpage>2056</lpage><pub-id pub-id-type="pmid">12473019</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hull</surname><given-names>M</given-names></name><name><surname>Strauss</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>M</given-names></name><name><surname>Volk</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name></person-group><article-title>Inflammatory mechanisms in Alzheimer's disease</article-title><source>Eur Arch Psychiatry Clin Neurosci</source><year>1996</year><volume>246</volume><fpage>124</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">8739396</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Madre</surname><given-names>JG</given-names></name><name><surname>Garcia</surname><given-names>JL</given-names></name><name><surname>Gonzalez</surname><given-names>RC</given-names></name><name><surname>Montero</surname><given-names>JM</given-names></name><name><surname>Paniagua</surname><given-names>EB</given-names></name><name><surname>Escribano</surname><given-names>JR</given-names></name><name><surname>Martinez</surname><given-names>JD</given-names></name><name><surname>Cenjor</surname><given-names>RF</given-names></name></person-group><article-title>Association between seropositivity to <italic>Chlamydia pneumoniae </italic>and acute ischaemic stroke</article-title><source>Eur J Neurol</source><year>2002</year><volume>9</volume><fpage>303</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">11985640</pub-id><pub-id pub-id-type="doi">10.1046/j.1468-1331.2002.00408.x</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawamoto</surname><given-names>R</given-names></name><name><surname>Kajiwara</surname><given-names>T</given-names></name><name><surname>Oka</surname><given-names>Y</given-names></name><name><surname>Takagi</surname><given-names>Y</given-names></name></person-group><article-title>An association between an antibody against <italic>Chlamydia pneumoniae </italic>and ischemic stroke in elderly Japanese</article-title><source>Intern Med</source><year>2003</year><volume>42</volume><fpage>571</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">12879948</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>SC</given-names></name><name><surname>Mayer</surname><given-names>O</given-names></name><name><surname>J&#x000fc;rgens</surname><given-names>S</given-names></name><name><surname>Vonthein</surname><given-names>R</given-names></name><name><surname>Schultze</surname><given-names>G</given-names></name><name><surname>Risler</surname><given-names>T</given-names></name><name><surname>Brehm</surname><given-names>BR</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>IgA seropositivity is associated with increased risk for atherosclerotic vascular disease, myocardial infarction and stroke in dialysis patients</article-title><source>Clin Nephrol</source><year>2003</year><volume>59</volume><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">12708567</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virok</surname><given-names>D</given-names></name><name><surname>Kis</surname><given-names>Z</given-names></name><name><surname>Karai</surname><given-names>L</given-names></name><name><surname>Intzedy</surname><given-names>L</given-names></name><name><surname>Burian</surname><given-names>K</given-names></name><name><surname>Szabo</surname><given-names>A</given-names></name><name><surname>Ivanyi</surname><given-names>B</given-names></name><name><surname>Gonczol</surname><given-names>E</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>in artherosclerotic middle cerebral artery</article-title><source>Stroke</source><year>2001</year><volume>32</volume><fpage>1973</fpage><lpage>1976</lpage><pub-id pub-id-type="pmid">11546883</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elkind</surname><given-names>MSV</given-names></name><name><surname>Lin</surname><given-names>I-F</given-names></name><name><surname>Grayston</surname><given-names>JT</given-names></name><name><surname>Sacco</surname><given-names>RL</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>and the risk of first ischemic stroke: the Northern Manhattan Stroke Study</article-title><source>Stroke</source><year>2000</year><volume>31</volume><fpage>1521</fpage><lpage>1525</lpage><pub-id pub-id-type="pmid">10884447</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fagerberg</surname><given-names>B</given-names></name><name><surname>Gnarpe</surname><given-names>J</given-names></name><name><surname>Gnarpe</surname><given-names>H</given-names></name><name><surname>Agewall</surname><given-names>S</given-names></name><name><surname>Wikstrand</surname><given-names>J</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: a prospective study in middle-aged to elderly men with treated hypertension</article-title><source>Stroke</source><year>1999</year><volume>30</volume><fpage>299</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">9933263</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>PJ</given-names></name><name><surname>Honeybourne</surname><given-names>D</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>Beevers</surname><given-names>DG</given-names></name><name><surname>Wise</surname><given-names>R</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project</article-title><source>Stroke</source><year>1998</year><volume>29</volume><fpage>404</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">9472881</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>GC</given-names></name><name><surname>Tatemichi</surname><given-names>TK</given-names></name><name><surname>Erkinjuntti</surname><given-names>T</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Masdeu</surname><given-names>JC</given-names></name><name><surname>Garcia</surname><given-names>JH</given-names></name><name><surname>Amaducci</surname><given-names>L</given-names></name><name><surname>Orgogozo</surname><given-names>JM</given-names></name><name><surname>Brun</surname><given-names>A</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Moody</surname><given-names>DM</given-names></name><name><surname>O'Brien</surname><given-names>MD</given-names></name><name><surname>Yamaguchi</surname><given-names>T</given-names></name><name><surname>Grafman</surname><given-names>J</given-names></name><name><surname>Drayer</surname><given-names>BP</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><name><surname>Ogata</surname><given-names>J</given-names></name><name><surname>Kokmen</surname><given-names>E</given-names></name><name><surname>Bermejo</surname><given-names>F</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name><name><surname>Gorelick</surname><given-names>PB</given-names></name><name><surname>Bick</surname><given-names>KL</given-names></name><name><surname>Pajeau</surname><given-names>AK</given-names></name><name><surname>Bell</surname><given-names>MA</given-names></name><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>Culebras</surname><given-names>A</given-names></name><name><surname>Korczyn</surname><given-names>AD</given-names></name><name><surname>Bogousslavsky</surname><given-names>J</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Scheinberg</surname><given-names>P</given-names></name></person-group><article-title>Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop</article-title><source>Neurology</source><year>1993</year><volume>43</volume><fpage>250</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">8094895</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Molloy</surname><given-names>DW</given-names></name><name><surname>Alemayehu</surname><given-names>E</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name></person-group><article-title>Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination</article-title><source>Am J Psychiatry</source><year>1991</year><volume>148</volume><fpage>102</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">1984692</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>BYL</given-names></name><name><surname>Gnarpe</surname><given-names>J</given-names></name><name><surname>Teo</surname><given-names>KK</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Prosser</surname><given-names>C</given-names></name><name><surname>Gibler</surname><given-names>WB</given-names></name><name><surname>Langer</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>W-C</given-names></name><name><surname>Armstrong</surname><given-names>PW</given-names></name></person-group><article-title>Does chronic <italic>Chlamydia pneumoniae </italic>infection increase the risk of myocardial injury? Insights from patients with non-ST-elevation acute coronary syndromes</article-title><source>Am Heart J</source><year>2002</year><volume>144</volume><fpage>987</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">12486422</pub-id><pub-id pub-id-type="doi">10.1067/mhj.2002.126734</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loeb</surname><given-names>MB</given-names></name><name><surname>Molloy</surname><given-names>DW</given-names></name><name><surname>Smieja</surname><given-names>M</given-names></name><name><surname>Standish</surname><given-names>T</given-names></name><name><surname>Goldsmith</surname><given-names>CH</given-names></name><name><surname>Mahony</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Borrie</surname><given-names>M</given-names></name><name><surname>Decoteau</surname><given-names>E</given-names></name><name><surname>Davidson</surname><given-names>W</given-names></name><name><surname>McDougall</surname><given-names>A</given-names></name><name><surname>Gnarpe</surname><given-names>J</given-names></name><name><surname>O'Donnell</surname><given-names>M</given-names></name><name><surname>Chernesky</surname><given-names>M</given-names></name></person-group><article-title>A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease</article-title><source>J Am Geriatr Soc</source><year>2004</year><volume>52</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">14962152</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>LA</given-names></name><name><surname>Kuo</surname><given-names>C-C</given-names></name><name><surname>Grayston</surname><given-names>JT</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>and cardiovascular disease</article-title><source>Emerg Infect Dis</source><year>1998</year><volume>4</volume><fpage>571</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">9866733</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kalayoglu</surname><given-names>MV</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Byrne</surname><given-names>GI</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>as an emerging risk factor in cardiovascular disease</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>2724</fpage><lpage>2731</lpage><pub-id pub-id-type="pmid">12460096</pub-id><pub-id pub-id-type="doi">10.1001/jama.288.21.2724</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belland</surname><given-names>RJ</given-names></name><name><surname>Ouellette</surname><given-names>SP</given-names></name><name><surname>Gieffers</surname><given-names>J</given-names></name><name><surname>Byrne</surname><given-names>GI</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>and atherosclerosis</article-title><source>Cell Microbiol</source><year>2004</year><volume>6</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">14706098</pub-id><pub-id pub-id-type="doi">10.1046/j.1462-5822.2003.00352.x</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ngeh</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Goodbourn</surname><given-names>C</given-names></name><name><surname>Panayiotou</surname><given-names>B</given-names></name><name><surname>McElligott</surname><given-names>G</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>in elderly patients with stroke (C-PEPS): a case-control study on the seroprevalence of <italic>Chlamydia pneumoniae </italic>in elderly patients with acute cerebrovascular disease</article-title><source>Cerebrovasc Dis</source><year>2003</year><volume>15</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">12499705</pub-id><pub-id pub-id-type="doi">10.1159/000067115</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Whincup</surname><given-names>P</given-names></name><name><surname>Lewington</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Lennon</surname><given-names>L</given-names></name><name><surname>Thomson</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>Y-K</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Ward</surname><given-names>M</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>IgA titres and coronary heart disease: prospective study and meta-analysis</article-title><source>Eur Heart J</source><year>2002</year><volume>23</volume><fpage>371</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">11846494</pub-id><pub-id pub-id-type="doi">10.1053/euhj.2001.2801</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Whincup</surname><given-names>P</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Lennon</surname><given-names>L</given-names></name><name><surname>Thomson</surname><given-names>A</given-names></name><name><surname>Appleby</surname><given-names>P</given-names></name><name><surname>Wong</surname><given-names>Y</given-names></name><name><surname>Bernardes-Silva</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>M</given-names></name></person-group><article-title><italic>Chlamydia pneumoniae </italic>IgG titres and coronary heart disease: prospective study and meta-analysis</article-title><source>BMJ</source><year>2000</year><volume>321</volume><fpage>208</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">10903653</pub-id><pub-id pub-id-type="doi">10.1136/bmj.321.7255.208</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strachan</surname><given-names>DP</given-names></name><name><surname>Carrington</surname><given-names>D</given-names></name><name><surname>Mendall</surname><given-names>MA</given-names></name><name><surname>Ballam</surname><given-names>L</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Butland</surname><given-names>BK</given-names></name><name><surname>Sweetnam</surname><given-names>PM</given-names></name><name><surname>Elwood</surname><given-names>PC</given-names></name></person-group><article-title>Relation of <italic>Chlamydia pneumoniae </italic>serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study</article-title><source>BMJ</source><year>1999</year><volume>318</volume><fpage>1035</fpage><lpage>1040</lpage><pub-id pub-id-type="pmid">10205100</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Breteler</surname><given-names>MM</given-names></name></person-group><article-title>Vascular risk factors for Alzheimer's disease: an epidemiologic perspective</article-title><source>Neurobiol Aging</source><year>2000</year><volume>21</volume><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">10867200</pub-id><pub-id pub-id-type="doi">10.1016/S0197-4580(99)00110-4</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pansari</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name></person-group><article-title>Alzheimer's disease and vascular factors: facts and theories</article-title><source>Int J Clin Pract</source><year>2002</year><volume>56</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">12018826</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Friedland</surname><given-names>RP</given-names></name></person-group><article-title>Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease</article-title><source>Neurobiol Aging</source><year>2000</year><volume>21</volume><fpage>357</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">10867221</pub-id><pub-id pub-id-type="doi">10.1016/S0197-4580(00)00119-6</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balin</surname><given-names>BJ</given-names></name><name><surname>Gerard</surname><given-names>HC</given-names></name><name><surname>Arking</surname><given-names>EJ</given-names></name><name><surname>Appelt</surname><given-names>DM</given-names></name><name><surname>Branigan</surname><given-names>PJ</given-names></name><name><surname>Abrams</surname><given-names>JT</given-names></name><name><surname>Whittum-Hudson</surname><given-names>JA</given-names></name><name><surname>Hudson</surname><given-names>AP</given-names></name></person-group><article-title>Identification and localization of <italic>Chlamydia pneumoniae </italic>in the Alzheimer's brain</article-title><source>Med Microbiol Immunol (Berl)</source><year>1998</year><volume>187</volume><fpage>23</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">9749980</pub-id><pub-id pub-id-type="doi">10.1007/s004300050071</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gieffers</surname><given-names>J</given-names></name><name><surname>Reusche</surname><given-names>E</given-names></name><name><surname>Solbach</surname><given-names>W</given-names></name><name><surname>Maass</surname><given-names>M</given-names></name></person-group><article-title>Failure to detect <italic>Chlamydia pneumoniae </italic>in brain sections of Alzheimer's disease patients</article-title><source>J Clin Microbiol</source><year>2000</year><volume>38</volume><fpage>881</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">10655406</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nochlin</surname><given-names>D</given-names></name><name><surname>Shaw</surname><given-names>CM</given-names></name><name><surname>Campbell</surname><given-names>LA</given-names></name><name><surname>Kuo</surname><given-names>CC</given-names></name></person-group><article-title>Failure to detect <italic>Chlamydia pneumoniae </italic>in brain tissue of Alzheimer's disease</article-title><source>Neurology</source><year>1999</year><volume>53</volume><fpage>1888</fpage><pub-id pub-id-type="pmid">10563652</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ring</surname><given-names>RH</given-names></name><name><surname>Lyons</surname><given-names>JM</given-names></name></person-group><article-title>Failure to detect <italic>Chlamydia pneumoniae </italic>in the late-onset Alzheimer's brain</article-title><source>J Clin Microbiol</source><year>2000</year><volume>38</volume><fpage>2591</fpage><lpage>2594</lpage><pub-id pub-id-type="pmid">10878049</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>GS</given-names></name><name><surname>Vipond</surname><given-names>IB</given-names></name><name><surname>Paul</surname><given-names>ID</given-names></name><name><surname>Matthews</surname><given-names>S</given-names></name><name><surname>Wilcock</surname><given-names>GK</given-names></name><name><surname>Caul</surname><given-names>EO</given-names></name></person-group><article-title>Failure to correlate <italic>C. pneumoniae </italic>with late onset Alzheimer's disease</article-title><source>Neurology</source><year>2002</year><volume>59</volume><fpage>142</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">12105327</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wozniak</surname><given-names>MA</given-names></name><name><surname>Cookson</surname><given-names>A</given-names></name><name><surname>Wilcock</surname><given-names>GK</given-names></name><name><surname>Itzhaki</surname><given-names>RF</given-names></name></person-group><article-title>Absence of <italic>Chlamydia pneumoniae </italic>in brain of vascular dementia patients</article-title><source>Neurobiol Aging</source><year>2003</year><volume>24</volume><fpage>761</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">12927758</pub-id><pub-id pub-id-type="doi">10.1016/S0197-4580(02)00236-1</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Curb</surname><given-names>JD</given-names></name><name><surname>Masaki</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>LR</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name></person-group><article-title>Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study</article-title><source>Ann Neurol</source><year>2002</year><volume>52</volume><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">12210786</pub-id><pub-id pub-id-type="doi">10.1002/ana.10265</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strandberg</surname><given-names>TE</given-names></name><name><surname>Tilvis</surname><given-names>RS</given-names></name></person-group><article-title>C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2000</year><volume>20</volume><fpage>1057</fpage><lpage>1060</lpage><pub-id pub-id-type="pmid">10764673</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Moreno</surname><given-names>C</given-names></name><name><surname>Dashe</surname><given-names>JF</given-names></name><name><surname>Scott</surname><given-names>T</given-names></name><name><surname>Thaler</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name></person-group><article-title>Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke</article-title><source>Stroke</source><year>2004</year><volume>35</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">14671251</pub-id><pub-id pub-id-type="doi">10.1161/01.STR.0000105391.62306.2E</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Engelhart</surname><given-names>MJ</given-names></name><name><surname>Geerlings</surname><given-names>MI</given-names></name><name><surname>Meijer</surname><given-names>J</given-names></name><name><surname>Kiliaan</surname><given-names>A</given-names></name><name><surname>Ruitenberg</surname><given-names>A</given-names></name><name><surname>van Swieten</surname><given-names>JC</given-names></name><name><surname>Stijnen</surname><given-names>T</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Witteman</surname><given-names>JCM</given-names></name><name><surname>Breteler</surname><given-names>MMB</given-names></name></person-group><article-title>Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study</article-title><source>Arch Neurol</source><year>2004</year><volume>61</volume><fpage>668</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">15148142</pub-id><pub-id pub-id-type="doi">10.1001/archneur.61.5.668</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGeer</surname><given-names>PL</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name><name><surname>Yasojima</surname><given-names>K</given-names></name></person-group><article-title>Alzheimer disease and neuroinflammation</article-title><source>J Neural Transm Suppl</source><year>2000</year><volume>59</volume><fpage>53</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">10961418</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yasojima</surname><given-names>K</given-names></name><name><surname>Schwab</surname><given-names>C</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><article-title>Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease</article-title><source>Brain Res</source><year>2000</year><volume>887</volume><fpage>80</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">11134592</pub-id><pub-id pub-id-type="doi">10.1016/S0006-8993(00)02970-X</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meade</surname><given-names>TW</given-names></name><name><surname>Mellows</surname><given-names>S</given-names></name><name><surname>Brozovic</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>GJ</given-names></name><name><surname>Chakrabarti</surname><given-names>RR</given-names></name><name><surname>North</surname><given-names>WR</given-names></name><name><surname>Haines</surname><given-names>AP</given-names></name><name><surname>Stirling</surname><given-names>Y</given-names></name><name><surname>Imeson</surname><given-names>JD</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group><article-title>Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study</article-title><source>Lancet</source><year>1986</year><volume>2</volume><fpage>533</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">2875280</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(86)90111-X</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stott</surname><given-names>DJ</given-names></name><name><surname>Spilg</surname><given-names>E</given-names></name><name><surname>Campbell</surname><given-names>AM</given-names></name><name><surname>Rumley</surname><given-names>A</given-names></name><name><surname>Mansoor</surname><given-names>MA</given-names></name><name><surname>Lowe</surname><given-names>GD</given-names></name></person-group><article-title>Haemostasis in ischaemic stroke and vascular dementia</article-title><source>Blood Coagul Fibrinolysis</source><year>2001</year><volume>12</volume><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">11734665</pub-id><pub-id pub-id-type="doi">10.1097/00001721-200112000-00006</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mari</surname><given-names>D</given-names></name><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Coppola</surname><given-names>R</given-names></name><name><surname>Bottasso</surname><given-names>B</given-names></name><name><surname>Reboldi</surname><given-names>GP</given-names></name><name><surname>Senin</surname><given-names>U</given-names></name><name><surname>Mannucci</surname><given-names>PM</given-names></name></person-group><article-title>Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease</article-title><source>Thromb Haemost</source><year>1996</year><volume>75</volume><fpage>216</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">8815562</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bots</surname><given-names>ML</given-names></name><name><surname>Breteler</surname><given-names>MMB</given-names></name><name><surname>van Kooten</surname><given-names>F</given-names></name><name><surname>Haverkate</surname><given-names>F</given-names></name><name><surname>Meijer</surname><given-names>P</given-names></name><name><surname>Koudstaal</surname><given-names>PJ</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Kluft</surname><given-names>C</given-names></name></person-group><article-title>Coagulation and fibrinolysis markers and risk of dementia: the Dutch Vascular Factors in Dementia Study</article-title><source>Haemostasis</source><year>1998</year><volume>28</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">10420069</pub-id><pub-id pub-id-type="doi">10.1159/000022433</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>GD</given-names></name><name><surname>Haverkate</surname><given-names>F</given-names></name></person-group><article-title>Specificity of haemostasis abnormalities for vascular phenotypes</article-title><source>Haemostasis</source><year>1998</year><volume>28</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">10420070</pub-id><pub-id pub-id-type="doi">10.1159/000022434</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smieja</surname><given-names>M</given-names></name><name><surname>Gnarpe</surname><given-names>J</given-names></name><name><surname>Lonn</surname><given-names>E</given-names></name><name><surname>Gnarpe</surname><given-names>H</given-names></name><name><surname>Olsson</surname><given-names>G</given-names></name><name><surname>Yi</surname><given-names>Q</given-names></name><name><surname>Dzavik</surname><given-names>V</given-names></name><name><surname>McQueen</surname><given-names>M</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name></person-group><article-title>Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>251</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">12538424</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000044940.65226.1F</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smieja</surname><given-names>M</given-names></name><name><surname>Mahony</surname><given-names>J</given-names></name><name><surname>Petrich</surname><given-names>A</given-names></name><name><surname>Boman</surname><given-names>J</given-names></name><name><surname>Chernesky</surname><given-names>M</given-names></name></person-group><article-title>Association of circulating <italic>Chlamydia pneumoniae </italic>DNA with cardiovascular disease: a systematic review</article-title><source>BMC Infect Dis</source><year>2002</year><volume>2</volume><fpage>21</fpage><pub-id pub-id-type="pmid">12359046</pub-id><pub-id pub-id-type="doi">10.1186/1471-2334-2-21</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kiecolt-Glaser</surname><given-names>JK</given-names></name><name><surname>Preacher</surname><given-names>KJ</given-names></name><name><surname>MacCallum</surname><given-names>RC</given-names></name><name><surname>Atkinson</surname><given-names>C</given-names></name><name><surname>Malarkey</surname><given-names>WB</given-names></name><name><surname>Glaser</surname><given-names>R</given-names></name></person-group><article-title>Chronic stress and age-related increases in the proinflammatory cytokine IL-6</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>9090</fpage><lpage>9095</lpage><pub-id pub-id-type="pmid">12840146</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1531903100</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von K&#x000e4;nel</surname><given-names>R</given-names></name><name><surname>Mills</surname><given-names>PJ</given-names></name><name><surname>Fainman</surname><given-names>C</given-names></name><name><surname>Dimsdale</surname><given-names>JE</given-names></name></person-group><article-title>Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease?</article-title><source>Psychosom Med</source><year>2001</year><volume>63</volume><fpage>531</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">11485106</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kiecolt-Glaser</surname><given-names>JK</given-names></name><name><surname>Glaser</surname><given-names>R</given-names></name><name><surname>Gravenstein</surname><given-names>S</given-names></name><name><surname>Malarkey</surname><given-names>WB</given-names></name><name><surname>Sheridan</surname><given-names>J</given-names></name></person-group><article-title>Chronic stress alters the immune response to influenza virus vaccine in older adults</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>3043</fpage><lpage>3047</lpage><pub-id pub-id-type="pmid">8610165</pub-id><pub-id pub-id-type="doi">10.1073/pnas.93.7.3043</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vedhara</surname><given-names>K</given-names></name><name><surname>Cox</surname><given-names>NK</given-names></name><name><surname>Wilcock</surname><given-names>GK</given-names></name><name><surname>Perks</surname><given-names>P</given-names></name><name><surname>Hunt</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>S</given-names></name><name><surname>Lightman</surname><given-names>SL</given-names></name><name><surname>Shanks</surname><given-names>NM</given-names></name></person-group><article-title>Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>627</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">10030328</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(98)06098-X</pub-id></citation></ref></ref-list></back></article>



